Experimental hypercalcaemia was induced in rats by (1) transplantation of the solid Walker 256 tumour, and (2) intraperitoneal injections of calcium gluconate. Whole blood clotting was studied by means of thromboelastography and whole blood clotting times in polystyrene and glass test tubes. At serum calcium levels between 10.3 and 11.5 m-equiv/l a slight delay in clot formation was found which...

Introduction Factor dosages are part of the diagnostic work up in patients with bleeding tendency (factor (F) VIII and FIX) or in thrombophilia screening (FVIII). The correct diagnosis of FVIII and FIX deficiency and the assessment of severity of the disease are essential for a patient-tailored treatment strategy. Persistently high levels of FVIII are regarded as a thrombophilia risk marker. FV...

"It is a sad reflection on the limitations of clinical trials that 20 years after the introduction of oral anti-coagulants their place in the long term management of coronary artery disease is still disputed". It is more of a reflection on the limitations of the tests used to control anticoagulants. For example, after the publication of the most recent M.R.C. report on the use of anticoagulants...

Histidine-rich glycoprotein (HRG) circulates in plasma at a concentration of 2μM and binds plasminogen, fibrinogen, and thrombospondin. Despite these interactions, the physiologic role of HRG is unknown. Previous studies have shown that mice and humans deficient in HRG have shortened plasma clotting times. To better understand this phenomenon, we examined the effect of HRG on clotting tests. HR...

The evolution of care in hemophilia is a remarkable story. Over the last 60 years, advances in protein purification, protein chemistry, donor screening, viral inactivation, gene sequencing, gene cloning, and recombinant protein production have dramatically enhanced the treatment and lives of patients with hemophilia. Recent efforts have produced enhanced half-life (EHL) clotting factors to bett...

Coagulation problems in pregnancy are primarily associated with overactivity of the intrinsic clotting system. This accounts for the increased incidence of thrombo-embolism during pregnancy. Where specific obstetric complications cause clotting problems the common underlying feature is usually placental pathology as in abruptio placentae, pre-eclampsia or hydatidiform mole. Abnormal activation ...